Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/3032
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Brinkhof, W. G. Martin | - |
dc.contributor.author | Egger, Matthias | - |
dc.contributor.author | Boulle, Andrew | - |
dc.contributor.author | May, Margaret | - |
dc.contributor.author | Hosseinipour, Mina | - |
dc.contributor.author | Sprinz, Eduardo | - |
dc.date.accessioned | 2020-03-16T12:18:32Z | - |
dc.date.available | 2020-03-16T12:18:32Z | - |
dc.date.issued | 2007-12 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/3032 | - |
dc.description.abstract | We examined the incidence of and risk factors for tuber- culosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the inci- dence of tuberculosis associated with highly active antiret- roviral therapy was similar: the rate ratio for months 7–12 versus months 1–3 was 0.48 (95% confidence interval, 0.36– 0.64) in low-income countries and 0.36 (95% confidence in- terval, 0.26–0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings | en_US |
dc.language.iso | en | en_US |
dc.publisher | Ampath | en_US |
dc.subject | Tuberculosis | en_US |
dc.subject | Antiretroviral | en_US |
dc.subject | Therapy | en_US |
dc.subject | Low-Income | en_US |
dc.subject | High-Income | en_US |
dc.title | Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Brinkhof, M.W.G. etal 2007.pdf | 126.24 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.